Press Release February 27, 2019

Caelum Biosciences, Alexion Announce Collaboration to Develop Targeted Antibody Therapy

Alston & Bird client Caelum Biosciences has entered into a collaboration with Alexion Pharmaceuticals, Inc., to develop a targeted therapy for light chain (AL) amyloidosis, a rare systemic disorder. 

Under the terms of the agreement, Alexion will acquire a minority equity interest in Caelum, with an exclusive option to acquire the remaining equity in the company. Alexion will make payments to Caelum totaling up to $60 million, including the purchase price for the equity and milestone-dependent development funding payments.

The collaboration also provides for potential additional payments of up to $500 million, including the upfront and regulatory and commercial milestone payments, in the event Alexion exercises the acquisition option.

A subsidiary of Alston & Bird client Fortress Biotech, Inc., Caelum is a Nasdaq-listed clinical-stage biotechnology company developing treatments for rare and life-threatening diseases.

Advising Caelum is an Alston & Bird team led by partners Mark McElreath and James Sullivan, senior associate Sean Doherty, and associates Gerard Hart and Matthew Barringer of the firm’s Corporate & Business Transactions Group.

Media Contact
Nicholas Clarke
Senior Communications Manager
Phone: 212.210.1222
This website uses cookies to improve functionality and performance. By continuing to browse this site, you are consenting to the use of cookies on this website. For details, see our Privacy Statement